Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoGenex' and Isis Pharmaceuticals' anticancer drug candidate OGX-011 has generated positive results in a trial evaluating the drug in combination with standard chemotherapy agents gemcitabine and cisplatin in patients with non-small cell lung cancer.
Subscribe to our email newsletter
The investigators concluded that OGX-011 in combination with the chemotherapeutic agents was well tolerated at the doses studied and most toxicities were typical for gemcitabine/cisplatin.
The one-year survival rate for the nine patients that received at least one dose of OGX-011 in combination with chemotherapy was 67%.
All but one of the nine patients showed either a partial response defined by a greater than or equal to 30% tumor size reduction, or stable disease defined by less than 30% tumor size reduction. Patient evaluation is still ongoing, and the median time for survival has not yet been reached.
“While this study was designed principally to evaluate safety in a limited number of patients, we are encouraged by the median and one-year survival rates to date,” said Dr Janessa Laskin, study chair and a medical oncologist at BC Cancer Agency.